Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07772882 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07772882 · ClinicalTrials.gov record · last posted 2026-08-19

Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer

Name: Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer — clinical trial record (NCT07772882)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1

SponsorRebecca Arend

Started2026-09

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is an open-label, Phase 1 clinical study to evaluate the safety, tolerability, PK profiles, and clinical activity of IV and PO arginine supplementation + SOC chemoimmunotherapy regimens in participants with PROC.

Trial Details

NCT Number	NCT07772882
Lead Sponsor	Rebecca Arend
Conditions	Platinum Resistant Ovarian Cancer, Fallopian Tube Cancers, Peritoneal Carcinoma
Enrollment	24 participants
Start Date	2026-09
Primary Completion	2028-10 (estimated)
Study Completion	2029-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-19